Changes in cardiac and vascular haemodynamics as potential mediators of improvements in cardiovascular and kidney outcomes with empagliflozin in type 2 diabetes.

Bernhard K Krämer,Sibylle J Hauske,Robert Chilton,Johannes F E Mann, Lars Gullestad,David Fitchett,Michaela Mattheus,Dominik Steubl,Christoph Wanner

Journal of diabetes and its complications（2023）

引用 0|浏览1

暂无评分

摘要

Improvements in haemodynamic parameters did not substantially mediate empagliflozin benefits on CV and kidney outcomes in patients with T2DM and established CV disease.

查看译文

关键词

Blood pressure,Cardiovascular disease,Empagliflozin,Haemodynamic,Mediation analysis,Sodium glucose cotransporter,Type 2 diabetes

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要